A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Conditions: Melanoma Interventions: Drug: relatlimab+nivolumab; Drug: relatlimab+nivolumab+rHuPH20; Drug: nivolumab; Drug: nivolumab+rHuPH20 Sponsors: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials